Secondary prevention after ischemic stroke -: Evolution over time in practice

被引:23
作者
Girot, M
Mackowiak-Cordoliani, MA
Deplanque, D
Hénon, H
Lucas, C
Leys, D [1 ]
机构
[1] Univ Lille, Roger Salengro Hosp, Dept Neurol, Stroke Dept, F-59037 Lille, France
[2] Univ Lille, Roger Salengro Hosp, Dept Pharmacol, F-59037 Lille, France
关键词
ischemia; prevention; risk factors;
D O I
10.1007/s00415-005-0591-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and objective An optimal management of vascular risk factors, associated with antithrombotic drugs and carotid surgery when appropriate, reduces the risk of a new vascular event after stroke. Although secondary prevention is not optimal in many patients in practice, the question of whether there is an improvement over time remains unanswered. The aim of our study was to test the hypothesis that secondary prevention measures after cerebral ischemia improve over time. Method We included 123 consecutive patients in 1994, and 125 consecutive patients in 2002, who were admitted to a neurological department for any reason and had had an episode of cerebral ischemia less than 6 years earlier. We compared the groups for the management of arterial hypertension, hypercholesterolemia, diabetes mellitus and smoking. We recorded the values of blood pressure, biological parameters, and presence of antithrombotic therapy, lipid-lowering and anti-hypertensive drugs. Whether patients were properly treated or not, was determined by a comparison between their current treatment and guidelines available when recruited. Results Prevention was not optimal in 96 of 123 (78%) patients in 1994, and in 77 of 125 (62%) in 2002. Vascular risk factors were better identified and managed in 2002 than in 1994, especially for hypercholesterolemia. Antithrombotic therapies, statins and antihypertensive drugs, except calcium channel blockers, were more often used in 2002. The proportion of patients in whom arterial hypertension and hypercholesterolemia were identified was higher in 2002, but the proportion of patients identified as diabetics remained stable. However, the proportion of patients with blood pressure > 140/90 mmHg, glycemia greater than or equal to 126 mg/dl, total cholesterol level greater than or equal to 240 mg/dl, or being current smokers, were significantly lower in 2002 than in 1994. Conclusion Although most of patients with previous cerebral ischemia did not receive an optimal management of their risk factors in 2002, there was an improvement over an 8-year period.
引用
收藏
页码:14 / 20
页数:7
相关论文
共 35 条
[1]   Supplement to the guidelines for the management of transient ischemic attacks - A statement from the Ad Hoc Committee on guidelines for the management of transient ischemic attacks, Stroke Council, American Heart Association [J].
Albers, GW ;
Hart, RG ;
Lutsep, HL ;
Newell, DW ;
Sacco, RL .
STROKE, 1999, 30 (11) :2502-2511
[2]  
[Anonymous], 1997, Eur Heart J, V18, P1569
[3]  
[Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
[4]   Risk factors and stroke prevention [J].
Bogousslavsky, J ;
Kaste, M ;
Olsen, TS ;
Hacke, W ;
Orgogozo, JM .
CEREBROVASCULAR DISEASES, 2000, 10 :12-21
[5]  
Chalmers J, 1999, CLIN EXP HYPERTENS, V21, P1009
[6]  
Clark CM, 1997, DIABETES CARE, V20, P1
[7]   BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J].
COLLINS, R ;
PETO, R ;
MACMAHON, S ;
HEBERT, P ;
FIEBACH, NH ;
EBERLEIN, KA ;
GODWIN, J ;
QIZILBASH, N ;
TAYLOR, JO ;
HENNEKENS, CH .
LANCET, 1990, 335 (8693) :827-838
[8]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[9]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[10]   Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? [J].
Deplanque, D ;
Corea, F ;
Arquizan, C ;
Parnetti, L ;
Mas, JL ;
Gallai, V ;
Leys, D .
HEART, 1999, 82 (05) :563-569